For instance, while mutation analysis of BRAF, RET, and RAS genes, which are part of the MAPK pathway, is already integrated into clinical practice for diagnostic and prognostic purposes in thyroid cancer [20], there is limited understanding of how genes within this pathway contribute to tumorigenesis in these tumors. The gene discussed is RET; the disease is thyroid gland carcinoma.